Patients with advanced hepatocellular carcinoma need a personalized management : A lesson from clinical practice
© 2017 by the American Association for the Study of Liver Diseases..
The Barcelona Clinic Liver Cancer (BCLC) advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study, our aim was to assess treatment and overall survival (OS) of BCLC C patients subclassified according to clinical features (performance status [PS], macrovascular invasion [MVI], extrahepatic spread [EHS] or MVI + EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analyzed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were subclassified as: PS1 alone (n = 385; 46.1%), PS2 alone (n = 146; 17.5%), MVI (n = 224; 26.8%), EHS (n = 51; 6.1%), and MVI + EHS (n = 29; 3.5%). MVI, EHS, and MVI + EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein (AFP) levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months), and MVI + EHS (3.1 months; P < 0.001). Among MVI patients, OS was longer in those with peripheral than with central (portal trunk) MVI (11.2 vs. 7.1 months; P = 0.005). The most frequent treatments were: curative approaches in PS1 (39.7%), supportive therapy in PS2 (41.8%), sorafenib in MVI (39.3%) and EHS (37.3%), and best supportive care in MVI + EHS patients (51.7%). Independent prognostic factors were: Model for End-stage Liver Disease score, Child-Pugh class, ascites, platelet count, albumin, tumor size, MVI, EHS, AFP levels, and treatment type.
CONCLUSION: BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this stage. The remaining patients should be subclassified according to PS and tumor features, and new patient-tailored therapeutic indications are needed. (Hepatology 2018;67:1784-1796).
| Errataetall: |
CommentIn: Hepatology. 2018 May;67(5):1663-1665. - PMID 29220550 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 67(2018), 5 vom: 22. Mai, Seite 1784-1796 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.10.2018 Date Revised 08.04.2022 published: Print-Electronic CommentIn: Hepatology. 2018 May;67(5):1663-1665. - PMID 29220550 Citation Status MEDLINE |
|---|
| doi: |
10.1002/hep.29668 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278260756 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278260756 | ||
| 003 | DE-627 | ||
| 005 | 20231225020140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hep.29668 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278260756 | ||
| 035 | |a (NLM)29159910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giannini, Edoardo Giovanni |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patients with advanced hepatocellular carcinoma need a personalized management |b A lesson from clinical practice |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.10.2018 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hepatology. 2018 May;67(5):1663-1665. - PMID 29220550 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 by the American Association for the Study of Liver Diseases. | ||
| 520 | |a The Barcelona Clinic Liver Cancer (BCLC) advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study, our aim was to assess treatment and overall survival (OS) of BCLC C patients subclassified according to clinical features (performance status [PS], macrovascular invasion [MVI], extrahepatic spread [EHS] or MVI + EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analyzed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were subclassified as: PS1 alone (n = 385; 46.1%), PS2 alone (n = 146; 17.5%), MVI (n = 224; 26.8%), EHS (n = 51; 6.1%), and MVI + EHS (n = 29; 3.5%). MVI, EHS, and MVI + EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein (AFP) levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months), and MVI + EHS (3.1 months; P < 0.001). Among MVI patients, OS was longer in those with peripheral than with central (portal trunk) MVI (11.2 vs. 7.1 months; P = 0.005). The most frequent treatments were: curative approaches in PS1 (39.7%), supportive therapy in PS2 (41.8%), sorafenib in MVI (39.3%) and EHS (37.3%), and best supportive care in MVI + EHS patients (51.7%). Independent prognostic factors were: Model for End-stage Liver Disease score, Child-Pugh class, ascites, platelet count, albumin, tumor size, MVI, EHS, AFP levels, and treatment type | ||
| 520 | |a CONCLUSION: BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this stage. The remaining patients should be subclassified according to PS and tumor features, and new patient-tailored therapeutic indications are needed. (Hepatology 2018;67:1784-1796) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a alpha-Fetoproteins |2 NLM | |
| 700 | 1 | |a Bucci, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Garuti, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Brunacci, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Lenzi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Valente, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Caturelli, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Cabibbo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Piscaglia, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Virdone, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Felder, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarese, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Foschi, Francesco Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Svegliati Baroni, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Rapaccini, Gian Lodovico |e verfasserin |4 aut | |
| 700 | 1 | |a Olivani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gasbarrini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Marco, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Morisco, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Zoli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Masotto, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Borzio, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Benvegnù, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Colecchia, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Nardone, Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardi, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisani, Franco |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Liver Cancer (ITA.LI.CA) group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 67(2018), 5 vom: 22. Mai, Seite 1784-1796 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2018 |g number:5 |g day:22 |g month:05 |g pages:1784-1796 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hep.29668 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2018 |e 5 |b 22 |c 05 |h 1784-1796 | ||